Vigil Neuroscience, Inc.: management transactions · United States · SEC (Form 4)

About Vigil Neuroscience, Inc.

Vigil Neuroscience, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker VIGL. Headquartered in Watertown, Massachusetts, in the United States, the company is a clinical-stage biotechnology business focused on neurodegenerative disease through a microglia-centered strategy. Founded in 2020, Vigil was built around the idea that restoring microglial function may help address both rare and broader neurodegenerative disorders. Its scientific positioning differentiates it from general neurology players by concentrating on a specific immune pathway in the brain. ([vigilneuro.com](https://www.vigilneuro.com/index?utm_source=openai)) Vigil’s core pipeline has revolved around two main programs. The lead clinical asset, iluzanebart, also known as VGL101, is a fully human monoclonal antibody agonist targeting TREM2, a receptor involved in maintaining microglial health and response to environmental signals. Iluzanebart has been developed for ALSP (adult-onset leukoencephalopathy with axonal spheroids and pigmented glia), a rare and severe neurodegenerative disease, and Vigil has reported clinical and biomarker data supporting its disease-modifying hypothesis. The second major program, VG-3927, is a small-molecule TREM2 agonist designed for common neurodegenerative diseases, with an initial focus on Alzheimer’s disease in genetically defined patient subsets. ([investors.vigilneuro.com](https://investors.vigilneuro.com/news-releases/news-release-details/vigil-neuroscience-provides-update-clinical-development-strategy/?utm_source=openai)) From a market-positioning standpoint, Vigil has been a niche, high-science company operating in an emerging area of neuroscience drug development. That positioning offers potential differentiation, but it also comes with the typical biotech risk profile: concentrated pipeline exposure, clinical and regulatory uncertainty, and ongoing capital needs. The company’s 2024 annual report stated that it had incurred recurring losses since inception and that there was substantial doubt about its ability to continue as a going concern, underscoring the financial fragility often seen in single-platform clinical biotechs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1827087/000095017025038329/vigl-20241231.htm)) Recent developments have been dominated by strategic M&A. On May 21, 2025, Vigil announced a definitive merger agreement under which Sanofi agreed to acquire the company for $8.00 per share in cash, with closing expected in Q3 2025. Sanofi also noted that it had made a $40 million strategic investment in Vigil in June 2024. Prior to the deal announcement, Vigil had been reporting 2025 updates on its 2024 results and progress across its TREM2 programs, including the IGNITE study for iluzanebart and continued work on VG-3927. For investors, VIGL is therefore best understood as a U.S. NASDAQ-listed clinical biotech whose standalone equity story became heavily shaped by the Sanofi transaction. ([nasdaq.com](https://www.nasdaq.com/press-release/vigil-neuroscience-enters-definitive-merger-agreement-be-acquired-sanofi-2025-05-21))